Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.
News|Articles|October 5, 2026
Q3 2026 Recap: Psychiatry News and Updates
Author(s)Chelsie Derman
Fact checked by: Tim Smith
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
Advertisement
Advertisement
Related to this article
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
Advertisement
Advertisement